Stephen Miller’s appointment as President Donald Trump’s chief of staff gives a long-time supporter of Make America Healthy Again a powerful position in Washington. For drug companies, health regulation could become more contentious as the movement presses its concerns about vaccines, psychiatric medicines and industry-backed research. An approaching vote on the next FDA commissioner offers an early test of how much that support will change policy.
Health Regulation Enters the White House Power Struggle
Miller’s appointment follows midterm elections that brought divisions within the MAGA coalition and the Make America Healthy Again movement into public view. Led by HHS Secretary Robert F. Kennedy Jr., MAHA has also become a source of disagreement inside the administration over agricultural chemicals and vaccines.
Calley Means, who stepped down as senior advisor at HHS last month, has been airing those disagreements in media appearances. On Joe Rogan’s podcast, Means described resistance to his efforts to get the government to examine glyphosate’s health effects more closely. Glyphosate is a disputed herbicide made primarily by Bayer. Means attributed the resistance to industry pressure before Trump issued an executive order that treated the chemical as important to national defense. His account puts an agricultural product at the center of a fight with implications for the administration’s broader approach to industry.
Means also challenged the FDA’s handling of Moderna’s new mRNA-based flu vaccine, a shot intended to protect against flu. During the summer, the agency first declined to assess the application, then changed course and approved the vaccine in August. Means alleged that the study had been designed unfairly and that the vaccine was ineffective. Those were his claims; the agency’s decision was an approval.
Dr. Marty Makary led the FDA during that period, but Means directed much of his criticism toward Susie Wiles, then Trump’s chief of staff. He blamed Wiles for the administration’s retreat from MAHA positions, including its skepticism toward vaccines.
Wiles’ departure and Miller’s arrival have encouraged some MAHA supporters who see an opening for the movement to regain influence. Miller has long advised Trump and is best known for his hardline approach to immigration. His support for MAHA also predates this appointment.
For pharma, the question right now is what all of this political fighting could do to decisions the government is already working through, and the Moderna vaccine is a good example of that. The vaccine was approved, but influential allies of the administration are still attacking it, which means companies have to separate a settled regulatory decision and a policy fight that could keep going around that decision.
FDA Nomination Puts Miller to an Early Test
Dr. Heidi Overton’s bid to lead the FDA lost momentum during the midterm elections, but hearings are underway again in the Senate, which has scheduled a health committee vote for Nov. 18. Wiles had been a key supporter of Overton.
Means has criticized the role Overton played in the glyphosate order, and some other MAHA supporters have questioned Overton’s views about vaccines. Several Republican senators have yet to give Overton strong support for confirmation. Miller’s response could offer a sense of whether Miller wants Overton in the job or would rather support someone more closely aligned with MAHA. Drug companies have several reasons to look at what Miller has done and said. Miller was a member of the commission behind The MAHA Report last year, and the report criticized pharmaceutical companies for their role in shaping public health and the way pharmaceutical companies conduct research.
Miller’s record and comments from Miller and Kennedy suggest some areas could get a closer look, while policy has already changed in other areas.
- An administration executive order gave glyphosate protection, but disagreement over glyphosate has continued.
- Means has raised questions publicly about both the study supporting Moderna’s approved flu vaccine and whether Moderna’s vaccine is effective.
- The White House said universal recommendations for childhood vaccines now apply to 11 diseases, down from 18.
- The August vaccine order calls for giving the MMR vaccines separately when individual versions become available.
- Antidepressants have become a focus as MAHA seeks to reduce excessive prescribing of drugs for psychiatric conditions.
- The MAHA Report flags concerns about ultra-processed foods and agricultural chemicals, and supports healthier eating habits and exercise.
- Studies funded by pharmaceutical companies could get a closer look as well, and the report says companies shape studies to make their drugs look favorable.
These questions reach across several parts of the drug business. For vaccine companies, there are questions about demand and the recommendations for using vaccines, and for companies developing psychiatric drugs, it remains unclear what potential guidance on prescribing might mean for their businesses. A closer look at evidence paid for by drug companies could also affect how programs in future drug pipelines are evaluated. Those questions remain open even with Miller now in the job.
What Vaccine Recommendations and Psychiatric Prescribing Could Mean for Patients
Trump signed an executive order in August called the Gold Standard Childhood Vaccine Recommendations, changing the recommendations used for years for routine childhood vaccinations. The order says children should get the components that make up MMR as separate vaccines once the individual products are available.
At the signing, Miller said parents face pressure to agree to multiple doses of vaccines for newborns, and that this way of giving vaccines had not been studied. Dr. Jake Scott challenged what Miller said. Scott is a clinical associate professor in infectious diseases at Stanford University School of Medicine, and Scott pointed to testing in clinical trials and safety checks that continue over longer periods. Following the recommendations on a broad scale could also have widespread health consequences, Scott said.
Clinicians and hospitals are left with political claims that evidence is missing and the research Scott pointed to, which tells a different story. A change in routine vaccine advice could affect the conversations clinicians have with families, and it could affect the choices families make about vaccination. The disagreement also carries more weight now that Miller has greater influence. It remains unclear how many people will follow the recommendations.
MAHA’s effort to change psychiatric prescribing has gained ground during the last year, too. MAHA wants less use of medications that MAHA considers excessive, particularly when children are taking them. Regulators have been paying closer attention to antidepressants.
Earlier this year, media reports said a ban covering certain SSRIs had been discussed by Kennedy and HHS officials. SSRIs are a class of antidepressants. HHS denied that it wanted a ban, but HHS also released a plan that week aimed at reducing what HHS sees as excessive psychiatric prescribing. The plan called for bringing experts together for discussions about treatment options for depression and other conditions. Media reports in July said officials from health care and regulatory agencies met that summer to talk about prescribing guidance that could be issued later.
FDA has not limited antidepressant access so far. Patients who are already receiving treatment should know that talking about a change is one thing and restricting access is another thing. Companies weighing potential risks for their products need to separate those two things as well.
Miller’s appointment could give MAHA more say as those discussions continue. It is still not clear whether more influence for MAHA will result in FDA taking formal action or in new guidance for clinicians, and Overton’s confirmation process could offer an early sign of how much influence MAHA has. What matters for patients’ access to treatment will be what the administration actually changes.
